Literature DB >> 31869599

NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity.

Yu Peng1, Jinyu Chen1, Yongqiang Dai2, Ying Jiang2, Wei Qiu2, Yong Gu3, Honghao Wang4.   

Abstract

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) and MS are the most common autoimmune inflammatory demyelinating diseases of the CNS. However, the mechanisms of pathogenesis are still unclear. nucleotide-binding leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3), an important protein of the innate immune system that is activated by mitochondrial DNA (mtDNA), has been reported to be associated with various autoimmune disorders.
OBJECTIVE: To assess the levels of cerebrospinal fluid (CSF) NLRP3, mtDNA and inflammation-associated cytokines (IL-1β, IL-6 and IL-17) in patients with NMOSD and MS, and to examine the correlations between these factors.
METHODS: 28 NMOSD patients, 15 MS patients, and 16 controls with non-inflammatory neurological diseases were recruited. NLRP3 inflammasome, IL-1β, IL-6 and IL-17 were measured by ELISA. CSF extracellular mtDNA was measured by qPCR. The severity of clinical presentation was evaluated by EDSS score.
RESULTS: CSF levels of NLRP3, mtDNA, IL-1β, IL-6 and IL-17 were higher in NMOSD patients than in controls. Elevated CSF NLRP3, mtDNA and IL-6 were found in MS patients compared with controls. CSF NLRP3 and IL-6 levels were significantly higher in NMOSD patients than in MS patients. The EDSS scores of NMOSD patients during relapse were positively correlated with CSF NLRP3 and mtDNA.
CONCLUSION: Our findings suggest that CSF levels of the NLRP3 inflammasome may serve as a diagnostic biomarker for distinguishing NMOSD and MS. Pyroptosis mediated by the NLRP3 inflammasome following mitochondrial damage may play an important role in the pathogenesis of these neuroinflammatory disorders, especially NMOSD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebrospinal fluid; Mitochondrial DNA; Multiple sclerosis; NLRP3 inflammasome; Neuromyelitis optica spectrum disorder

Year:  2019        PMID: 31869599     DOI: 10.1016/j.msard.2019.101888

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  6 in total

1.  FANCC deficiency mediates microglial pyroptosis and secondary neuronal apoptosis in spinal cord contusion.

Authors:  Mingjie Xia; Xinyu Li; Suhui Ye; Qinyang Zhang; Tianyu Zhao; Rulin Li; Yanan Zhang; Minghan Xian; Tianqi Li; Haijun Li; Xin Hong; Shengnai Zheng; Zhanyang Qian; Lei Yang
Journal:  Cell Biosci       Date:  2022-06-03       Impact factor: 9.584

Review 2.  Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics.

Authors:  Yueran Cui; Haiyang Yu; Zhongqi Bu; Lulu Wen; Lili Yan; Juan Feng
Journal:  Front Mol Neurosci       Date:  2022-05-25       Impact factor: 6.261

3.  Cerebrospinal fluid cells immune landscape in multiple sclerosis.

Authors:  Yongchao Liu; Aili Jia; Zijian Li; Yueran Cui; Juan Feng
Journal:  J Transl Med       Date:  2021-03-25       Impact factor: 5.531

4.  NLRP3 in the Cerebrospinal Fluid as a Potential Biomarker for the Diagnosis and Prognosis of Community-Acquired Bacterial Meningitis in Adults.

Authors:  Zhe Gong; Chaopeng Zhang; Yanfei Li; Lijun Jing; Ranran Duan; Yaobing Yao; Junfang Teng; Yanjie Jia
Journal:  Front Cell Infect Microbiol       Date:  2022-01-25       Impact factor: 5.293

5.  The CSF Levels of Neutrophil-Related Chemokines in Patients with Neuromyelitis Optica.

Authors:  Zhuhe Liu; Jinyu Chen; Zhanhang Wang; Yao Wang; Dong Zheng; Honghao Wang; Yu Peng
Journal:  Ann Clin Transl Neurol       Date:  2020-06-09       Impact factor: 4.511

Review 6.  Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets.

Authors:  Vaidya Govindarajan; Juan Pablo de Rivero Vaccari; Robert W Keane
Journal:  J Neuroinflammation       Date:  2020-09-02       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.